Clinical trials
Completed Phase 3 trials in Greece
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
996 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 6 |
| 2001 | 14 |
| 2002 | 12 |
| 2003 | 35 |
| 2004 | 29 |
| 2005 | 32 |
| 2006 | 48 |
| 2007 | 49 |
| 2008 | 60 |
| 2009 | 50 |
| 2010 | 57 |
| 2011 | 52 |
| 2012 | 57 |
| 2013 | 55 |
| 2014 | 43 |
| 2015 | 59 |
| 2016 | 45 |
| 2017 | 63 |
| 2018 | 44 |
| 2019 | 40 |
| 2020 | 52 |
| 2021 | 28 |
| 2022 | 22 |
| 2023 | 20 |
| 2024 | 8 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 996 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 94 |
| Hoffmann-La Roche | 72 |
| Boehringer Ingelheim | 50 |
| Eli Lilly and Company | 50 |
| Sanofi | 48 |
| GlaxoSmithKline | 45 |
| Novo Nordisk A/S | 41 |
| Amgen | 40 |
| Pfizer | 40 |
| Bristol-Myers Squibb | 37 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 70 |
| Carcinoma, Non-Small-Cell Lung | 60 |
| Breast Neoplasms | 43 |
| Multiple Myeloma | 32 |
| Diabetes Mellitus | 30 |
| Pulmonary Disease, Chronic Obstructive | 30 |
| Arthritis, Rheumatoid | 28 |
| Neoplasms | 28 |
| Recurrence | 24 |
| Multiple Sclerosis | 20 |
Trials
Showing 1 to 25 of 996. Each trial links to its page on Pharma Observatory.
896 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.